Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
47 hedge funds and large institutions have $255M invested in Adaptimmune Therapeutics in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 9 closing their positions.
228% more capital invested
Capital invested by funds: $77.9M → $255M (+$177M)
77% more call options, than puts
Call options by funds: $168K | Put options by funds: $95K
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
9% more funds holding
Funds holding: 43 → 47 (+4)
4.61% more ownership
Funds ownership: 10.32% → 14.93% (+4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$41.6M |
| 2 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$21.3M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$12.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$6.81M |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$4.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$3.49M |
| 2 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
-$1.01M |
| 3 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
-$356K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$278K |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
-$185K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAS
51
Partnervest Advisory Services
Santa Barbara,
California
| – | -$42K | -35,000 | Closed |
|
52
Marshall Wace
London,
United Kingdom
| – | -$35K | -29,102 | Closed |
|
|
PP
53
Paloma Partners
Greenwich,
Connecticut
| – | -$33K | -27,400 | Closed |
|
|
CG
54
Cutler Group
San Francisco,
California
| – | -$8.96K | -2,700 | Closed |
|
ADAP Hedge Fund Activity: Q1 2020 in Review
47 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2020, worth a combined $255M — up 228% from $77.9M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ADAP positions and 9 closed out — a net gain of 5 holders — while 14 added to existing stakes and 10 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $41.6M. The largest seller was Man Group, cutting an estimated $3.49M.
- 47 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2020, up from 43 in Q4 2019.
- Funds reported $255M of Adaptimmune Therapeutics stock for Q1 2020, up 228% quarter-over-quarter.
- 14 funds opened new Adaptimmune Therapeutics positions in Q1 2020 and 9 closed out, a net change of +5 holders.
- The largest Adaptimmune Therapeutics buyer in Q1 2020 was RA Capital Management, an estimated $41.6M added.
- The largest Adaptimmune Therapeutics seller in Q1 2020 was Man Group, an estimated $3.49M sold.
Based on aggregated 13F filings for Q1 2020.